In vitro activities of tosufloxacin and five quinolones against 1,112 bacterial clinical isolates

Japanese Journal of Chemotherapy

Volumn 44, Issue 7, 1996, Pages 483-492

  Matsuzaki, Kaoru ^a   Uchino, Utsuki ^a   Muraoka, Hiroe ^a   Toda, Haruyo ^a   Kanayama, Akiko ^a   Saika, Takeshi ^a   Sato, Yumie ^a   Teduka, Kouichi ^a   Hasegawa, Miyuki ^a   Kobayashi, Intetsu ^a,b   Yamaguchi, Keizo ^b  

^a LSI MEDIENCE CORPORATION   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

clinical isolate; MIC; new quinolone

Indexed keywords

CIPROFLOXACIN; FLEROXACIN; LEVOFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TOSUFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; HUMAN; HUMAN CELL; ISOLATION PROCEDURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PROPIONIBACTERIACEAE; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES;

EID: 9444255781     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Maple PAC, Hamilton-Miller J M T, Brumfitt W: Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 35: 345-350, 1991
2. Ito H, Yoshida H, Bogaki-Shonai M, Niga T, Hattori H, Nakamura S: Quinolone resistance mutation in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 38: 2014-2023, 1994
3. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M: Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. Journal of Bacteriology 172: 6942-6949, 1990
4. Yoshida S, Kojima T, Inoue M, Mitsuhashi S: Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 35: 368-370, 1991
5. Kern W V, Andriof E, Oethinger M, Kern P, Hacker J, Marre R: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38: 681-687, 1994
6. Piddock L J V, Griggs D J, Hall M C, Jin Y F: Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother 37: 662-666, 1993
7. Piddock L J V: New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 38: 163-169, 1994
8. Poole K, Krebes K, McNally C, Neshat S: Multiple antibiotic resistance in Pseudomonas aeruginosa: Evidence for involvement of an efflux operon. Journal of Bacteriology 175: 7363-7372, 1993
9. Marshall A J H, Piddock L J V: Interaction of divalent cations, quinolones and bacteria. Journal of Antimicrobial Chemotherapy 34: 465-483, 1994
10. Resistance in Gonococci isolated in the WHO Western Pacific Region to various antimicrobials used in the treatment of gonorrhoea. In Sensitivity testing of Neisseria gonorrhoeae, WHO Western Pacific Regional Resistance Surveillance programme, 1994.
11. Tanaka M, Matsumoto T, Kobayashi I, Uchino U, Kumazawa J: Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeas isolated in Japan. Antimicrob Agents Chemother 39: 2367 -2370, 1995